EPA:SAN • FR0000120578
The current stock price of SAN.PA is 76.39 EUR. Today SAN.PA is down by -1.72%. In the past month the price decreased by -4.94%. In the past year, price decreased by -30.31%.
ChartMill assigns a technical rating of 0 / 10 to SAN.PA. When comparing the yearly performance of all stocks, SAN.PA is a bad performer in the overall market: 89.63% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to SAN.PA. While SAN.PA is still in line with the averages on profitability rating, there are concerns on its financial health.
On January 29, 2026 SAN.PA reported an EPS of 1.53 and a revenue of 11.30B. The company beat EPS expectations (4.58% surprise) and missed revenue expectations (-2.08% surprise).
30 analysts have analysed SAN.PA and the average price target is 98.37 EUR. This implies a price increase of 28.78% is expected in the next year compared to the current price of 76.39.
For the next year, analysts expect an EPS growth of 8.1% and a revenue growth 6.17% for SAN.PA
Over the last trailing twelve months SAN.PA reported a non-GAAP Earnings per Share(EPS) of 7.82. The EPS increased by 1.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.19 | 187.692B | ||
| 1SAN | SANOFI | 9.18 | 187.378B | ||
| UNC | UCB SA | 25.58 | 51.176B | ||
| UCB | UCB SA | 24.41 | 50.164B | ||
| MRK | MERCK KGAA | 12.81 | 49.217B | ||
| BAYN | BAYER AG-REG | 7.45 | 37.111B | ||
| 1BAYN | BAYER AG-REG | 7.7 | 36.973B | ||
| IPN | IPSEN | 14.11 | 13.795B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.15 | 9.95B | ||
| VIRP | VIRBAC SA | 16.31 | 2.907B | ||
| DMP | DERMAPHARM HOLDING SE | 15.27 | 2.062B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 82878
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of SAN.PA is 76.39 EUR. The price decreased by -1.72% in the last trading session.
SANOFI (SAN.PA) has a dividend yield of 3.8%. The yearly dividend amount is currently 3.79.
SAN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
SANOFI (SAN.PA) operates in the Health Care sector and the Pharmaceuticals industry.
SANOFI (SAN.PA) currently has 82878 employees.
SANOFI (SAN.PA) will report earnings on 2026-04-23.